Glypressin

Glypressin is an injectable solution containing the vasopressin analog terlipressin acetate. The product is supplied in a sterile aqueous formulation for intravenous administration. Glypressin is marketed in the European Union as a prescription‑only medication. It belongs to the vasoconstrictor therapeutic class and acts as a V1 receptor agonist to reduce portal pressure. The strength of the preparation is not specified in the currently publicly available data.

Glypressin is indicated for several acute conditions where rapid vasoconstriction is required. It is used under medical supervision in hospital settings to manage life‑threatening bleeding and circulatory failure.

- Control of acute esophageal variceal bleeding in patients with portal hypertension. - Treatment of hepatorenal syndrome type 1 to improve renal perfusion. - Adjunctive therapy for septic shock refractory to standard vasopressors. - Temporary reduction of portal venous pressure during endoscopic procedures. - Support of systemic blood pressure in patients with advanced liver disease undergoing transplantation. - Management of other severe hemorrhagic episodes where vasopressin analogs are appropriate.

The safety profile of Glypressin reflects its potent vasoconstrictive activity. Adverse reactions are reported across a range of frequencies and severities.

Common: - Mild to moderate headache - Transient nausea or vomiting - Abdominal discomfort or cramps - Flushing or warmth at the infusion site - Mild hyponatremia

Serious: - Myocardial ischemia or infarction - Severe hypertension or hypertensive crisis - Cardiac arrhythmias, including tachycardia - Ischemic limb or digital necrosis - Pulmonary edema

Because Glypressin produces potent vasoconstriction, careful patient selection and monitoring are essential. The following precautions should be observed before and during therapy.

- Assess cardiovascular status; avoid use in patients with recent myocardial infarction. - Monitor blood pressure frequently; discontinue if severe hypertension develops. - Evaluate renal function; dose adjustment may be needed in renal impairment. - Use with caution in patients with peripheral vascular disease or severe atherosclerosis. - Avoid in uncontrolled sepsis without adequate source control. - Consider fetal risk; pregnancy category is unknown, so use only if benefits outweigh risks. - Ensure appropriate fluid balance to reduce risk of ischemia.

Glypressin can modify the effects of other cardiovascular and vasoactive agents. Interaction potential is categorized as either to avoid or to use with caution.

Avoid: - Concurrent use with other vasopressin analogs or potent vasoconstrictors (e.g., norepinephrine) due to additive hypertension. - Combination with phosphodiesterase‑5 inhibitors (e.g., sildenafil) because of unpredictable vascular responses. - Co‑administration with drugs that prolong the QT interval.

Use with caution: - Concurrent beta‑blockers, which may mask tachycardia. - Diuretics, which can exacerbate renal hypoperfusion. - Anticoagulants, as reduced portal pressure may alter bleeding risk. - Sedatives or anesthetics that depress cardiovascular reflexes.